ST. LOUIS — AstraZeneca has acquired St. Louis-based vaccine startup Omniose, bringing the local company’s vaccine-engineering platform and researchers into the global drugmaker’s infectious-disease operation.
Omniose announced the transaction Tuesday. Financial terms were not disclosed. The preclinical biotechnology company develops conjugate vaccines designed to help the immune system recognize bacteria that can cause serious infections.
The acquisition follows a research collaboration between the companies that began in 2024. AstraZeneca said Omniose’s bioconjugation platform could support preclinical vaccine programs and complement its existing capabilities.
Omniose was formed in St. Louis and grew through local startup support as well as federal research grants. The transaction is a significant outcome for the region’s biotechnology ecosystem, although the companies did not announce local employment commitments or operating plans beyond the integration into AstraZeneca’s infectious-disease unit.
The companies also did not disclose a closing price or provide a product timetable. Because Omniose’s programs remain preclinical, any vaccine candidates would still face additional testing and regulatory review before possible public use.
For St. Louis, the deal underscores the commercial value of research companies built around university, federal and regional investment networks. Its longer-term effect on local staffing and facilities will depend on AstraZeneca’s integration decisions.
Sources: Omniose announcement and Reuters.
